GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Glycorex Transplantation AB (NGM:GTAB B) » Definitions » Debt-to-Equity

Glycorex Transplantation AB (NGM:GTAB B) Debt-to-Equity : 0.21 (As of Sep. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Glycorex Transplantation AB Debt-to-Equity?

Glycorex Transplantation AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was kr4.48 Mil. Glycorex Transplantation AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was kr8.45 Mil. Glycorex Transplantation AB's Total Stockholders Equity for the quarter that ended in Sep. 2023 was kr60.64 Mil. Glycorex Transplantation AB's debt to equity for the quarter that ended in Sep. 2023 was 0.21.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Glycorex Transplantation AB's Debt-to-Equity or its related term are showing as below:

NGM:GTAB B' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1   Med: 0.12   Max: 0.25
Current: 0.21

During the past 11 years, the highest Debt-to-Equity Ratio of Glycorex Transplantation AB was 0.25. The lowest was 0.10. And the median was 0.12.

NGM:GTAB B's Debt-to-Equity is ranked worse than
57.44% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs NGM:GTAB B: 0.21

Glycorex Transplantation AB Debt-to-Equity Historical Data

The historical data trend for Glycorex Transplantation AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glycorex Transplantation AB Debt-to-Equity Chart

Glycorex Transplantation AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.23 0.10 0.11 0.14

Glycorex Transplantation AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.14 0.16 0.21 0.21

Competitive Comparison of Glycorex Transplantation AB's Debt-to-Equity

For the Biotechnology subindustry, Glycorex Transplantation AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glycorex Transplantation AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Glycorex Transplantation AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Glycorex Transplantation AB's Debt-to-Equity falls into.



Glycorex Transplantation AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Glycorex Transplantation AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Glycorex Transplantation AB's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Glycorex Transplantation AB  (NGM:GTAB B) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Glycorex Transplantation AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Glycorex Transplantation AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Glycorex Transplantation AB (NGM:GTAB B) Business Description

Traded in Other Exchanges
N/A
Address
Solvegatan 41, Lund, SWE, 223 70
Glycorex Transplantation AB is a biotechnology company. The company is involved in the development, production, and sales of organ transplantation. Its product includes Glycosorb-ABO which facilitates the transplantation of organs over the blood group barriers. The group has more than 130 transplant centers in approximately 23 countries.

Glycorex Transplantation AB (NGM:GTAB B) Headlines

No Headlines